Eosinophils and asthma

Lemanske RF Jr, Busse WW: 6. Asthma: Factors underlying inception, exacerbation, and disease progression. J Allergy Clin Immunol 2006, 117:S456–S461. Larche M, Robinson DS, Kay AB: The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003, 111:450–463; quiz 464. Miyahara N, Swanson BJ, Takeda K, et al.: Effector CD8(+) T cells mediate inflammation and airway hyperresponsiveness. Nat Med 2004, 10:865–869. Akbari O, Faul JL, Hoyte EG, et al.: CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N Engl J Med 2006, 354:1117–1129. Huber HL, Koessler KK: The pathology of bronchial asthma. Arch Intern Med 1922, 30:689–760. Tomassini M, Tsicopoulos A, Tai PC, et al.: Release of granule proteins by eosinophils from allergic and nonallergic patients with eosinophilia on immunoglobulin-dependent activation. J Allergy Clin Immunol 1991, 88:365–375. Bousquet J, Chanez P, Lacoste JY, et al.: Eosinophilic inflammation in asthma. N Engl J Med 1990, 323:1033–1039. [Comment in N Engl J Med 1991, 324:1514–1515.] Stelmach I, Majak P, Grzelewski T, et al.: The ECP/Eo count ratio in children with asthma. J Asthma 2004, 41:539–546. Venge P: Monitoring the allergic inflammation. Allergy 2004, 59:26–32. Bradley A: Mining the mouse genome. Nature 2002, 420:512–514. Sanderson CJ: Interleukin-5 and the regulation of eosinophil production. In Immunopharmacology of Eosinophils. Edited by Smith H, Cook RM. Epsom, Surrey, UK: Academic Press; 1993:11–24. Mathur M, Herrmann K, Li X, et al.: TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma. Am J Respir Crit Care Med 1999, 159:580–587. Lee JJ, McGarry MP, Farmer SC, et al.: Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med 1997, 185:2143–2156. Zhu Z, Homer RJ, Wang Z, et al.: Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999, 103:779–788. Kanehiro A, Takeda K, Joetham A, et al.: Timing of administration of anti-VLA-4 differentiates airway hyperresponsiveness in the central and peripheral airways in mice. Am J Respir Crit Care Med 2000, 162:1132–1139. Henderson WR Jr, Chiang GK, Tien YT, Chi EY: Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006, 173:718–728. Shen HH, Ochkur SI, McGarry MP, et al.: A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse. J Immunol 2003, 170:3296–3305. Justice JP, Borchers MT, Crosby JR, et al.: Ablation of eosinophils leads to a reduction of allergen-induced pulmonary pathology. Am J Physiol Lung Cell Mol Physiol 2003, 284:L169–178. Lee JJ, Dimina D, Macias MP, et al.: Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004, 305:1773–1776. Humbles AA, Lloyd CM, McMillan SJ, et al.: A critical role for eosinophils in allergic airways remodeling. Science 2004, 305:1776–1779. Leckie MJ, ten Brinke A, Khan J, et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144–2148. O’Byrne PM, Inman MD, Parameswaran K: The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 2001, 108:503–508. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS: Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003, 167:199–204. Flood-Page P, Menzies-Gow A, Phipps S, et al.: Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003, 112:1029–1036. Wardlaw AJ: Eosinophil trafficking in asthma. Clin Med 2001, 1:214–218. Pitchford SC, Momi S, Giannini S, et al.: Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood 2005, 105:2074–2081. Ying S, Meng Q, Zeibecoglou K, et al.: Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. J Immunol 1999, 163:6321–6329. Teixeira MM, Giembycz MA, Lindsay MA, Hellewell PG: Pertussis toxin shows distinct early signaling events in platelet-activating factor-, leukotriene B4-, and C5a-induced eosinophil homotypic aggregation in vitro and recruitment in vivo. Blood 1997, 89:4566–4573. Southam DS, Widmer N, Ellis R, et al.: Increased eosinophil-lineage committed progenitors in the lung of allergen-challenged mice. J Allergy Clin Immunol 2005, 115:95–102. Gleich GJ, Adolphson CR: The eosinophil and bronchial asthma: evidence for a critical role of eosinophils in pathophysiology. In Interleukin-5: From Molecule to Drug Target for Asthma. Edited by Sanderson CJ. New York: Marcel Dekker; 1999:1–37. Lee JJ, Lee NA: Eosinophil degranulation: an evolutionary vestige or a universally destructive effector function? Clin Exper Allergy 2005, 35:986–994. Walsh GM: Eosinophil granule proteins and their role in disease. Curr Opin Hematol 2001, 8:28–33. Brottman GM, Regelmann WE, Slungaard A, Wangensteen OD: Effect of eosinophil peroxidase on airway epithelial permeability in the guinea pig. Pediatr Pulmonol 1996, 21:159–166. Rochester CL, Ackerman SJ, Zheng T, Elias JA: Eosinophilfibroblast interactions: granule major basic protein interacts with IL-1 and transforming growth factor-beta in the stimulation of lung fibroblast IL-6-type cytokine production. J Immunol 1996, 156:4449–4456. Rabe KF, Munoz NM, Vita AJ, et al.: Contraction of human bronchial smooth muscle caused by activated human eosinophils. Am J Physiol 1994, 267:L326–334. Evans CM, Fryer AD, Jacoby DB, et al.: Pretreatment with antibody to eosinophil major basic protein prevents hyperresponsiveness by protecting neuronal M2 muscarinic receptors in antigen-challenged guinea pigs. J Clin Invest 1997, 100:2254–2262. Wang JG, Mahmud SA, Thompson JA, et al.: The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 2006, 107:558–565. Haskell MD, Moy JN, Gleich GJ, Thomas LL: Analysis of signaling events associated with activation of neutrophil superoxide anion production by eosinophil granule major basic protein. Blood 1995, 86:4627–4637. Piliponsky AM, Pickholtz D, Gleich GJ, Levi-Schaffer F: Human eosinophils induce histamine release from antigen-activated rat peritoneal mast cells: a possible role for mast cells in late-phase allergic reactions. J Allergy Clin Immunol 2001, 107:993–1000. Voehringer D, Shinkai K, Locksley RM: Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. Immunity 2004, 20:267–277. Justice JP, Borchers MT, Lee JJ, et al.: Ragweed-induced expression of GATA-3, IL-4, and IL-5 by eosinophils in the lungs of allergic C57BL/6J mice. Am J Physiol Lung Cell Mol Physiol 2002, 282:L302–309. Lamkhioued B, Gounni AS, Aldebert D, et al.: Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils. Ann N Y Acad Sci 1996, 796:203–208. Lim KG, Wan HC, Resnick M, et al.: Human eosinophils release the lymphocyte and eosinophil active cytokines, RANTES and lymphocyte chemoattractant factor. Int Arch Allergy Immunol 1995, 107:342. Shi HZ, Humbles A, Gerard C, et al.: Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest 2000, 105:945–953. MacKenzie JR, Mattes J, Dent LA, Foster PS: Eosinophils promote allergic disease of the lung by regulating CD4+ Th2 lymphocyte function. J Immunol 2001, 167:3146–3155. Odemuyiwa SO, Ghahary A, Li Y, et al.: Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J Immunol 2004, 173:5909–5913. Mitra SN, Slungaard A, Hazen SL: Role of eosinophil peroxidase in the origins of protein oxidation in asthma. Redox Rep 2000, 5:215–224. Kaminsky DA, Mitchell J, Carroll N, et al.: Nitrotyrosine formation in the airways and lung parenchyma of patients with asthma. J Allergy Clin Immunol 1999, 104:747–754. Berry MA, Shaw DE, Green RH, et al.: The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005, 35:1175–1179. Bandeira-Melo C, Bozza PT, Weller PF: The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol 2002, 109:393–400. Lee T, Lenihan DJ, Malone B, et al.: Increased biosynthesis of platelet-activating factor in activated human eosinophils. J Biol Chem 1984, 259:5526–5530. Weller PF, Lee CW, Foster DW, et al.: Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci U S A 1983, 80:7626–7630. Carey MA, Germolec DR, Langenbach R, Zeldin DC: Cyclooxygenase enzymes in allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids 2003, 69:157–162. Luster AD, Tager AM: T-cell trafficking in asthma: lipid mediators grease the way. Nat Rev Immunol 2004, 4:711–724. Nagata M, Saito K: The roles of cysteinyl leukotrienes in eosinophilic inflammation of asthmatic airways. Int Arch Allergy Immunol 2003, 131(Suppl 1):7–10. Uhlig S, Wollin L, Wendel A: Contributions of thromboxane and leukotrienes to PAF-induced impairment of lung function in the rat. J Appl Physiol 1994, 77:262–269. Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B: Leukotrienes are potent constrictors of human bronchi. Nature 1980, 288:484–486. Mita H, Hasegawa M, Saito H, Akiyama K: Levels of cysteinyl leukotriene receptor mRNA in human peripheral leucocytes: significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils. Clin Exp Allergy 2001, 31:1714–1723. Fujii M, Tanaka H, Abe S: Interferon-gamma up-regulates expression of cysteinyl leukotriene type 2 receptors on eosinophils in asthmatic patients. Chest 2005, 128:3148–3155. Williams TJ: The eosinophil enigma. J Clin Invest 2004, 113:507–509. Pascual RM, Peters SP: Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol 2005, 116:477–486. Tschumperlin DJ, Drazen JM: Chronic effects of mechanical force on airways. Annu Rev Physiol 2006, 68:563–583. Cho JY, Miller M, Baek KJ, et al.: Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest 2004, 113:551–560. Minshall EM, Leung DY, Martin RJ, et al.: Eosinophil-associated TGF-betal mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1997, 17:326–333. Horiuchi T, Weller PF: Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol 1997, 17:70–77. Stenfeldt AL, Wenneras C: Danger signals derived from stressed and necrotic epithelial cells activate human eosinophils. Immunology 2004, 112:605–614. Kobayashi H, Gleich GJ, Butterfield JH, Kita H: Human eosinophils produce neurotrophins and secrete nerve growth factor on immunologic stimuli. Blood 2002, 99:2214–2220. Ohno I, Nitta Y, Yamauchi K, et al.: Eosinophils as a potential source of platelet-derived growth factor B-chain (PDGF-B) in nasal polyposis and bronchial asthma. Am J Respir Cell Mol Biol 1995, 13:639–647. Wiehler S, Cuvelier SL, Chakrabarti S, Patel KD: p38 MAP kinase regulates rapid matrix metalloproteinase-9 release from eosinophils. Biochem Biophys Res Commun 2004, 315:463–470. Kelly EA, Busse WW, Jarjour NN: Increased matrix metalloproteinase-9 in the airway after allergen challenge. Am J Respir Crit Care Med 2000, 162(3 Pt 1):1157–1161. Pope SM, Fulkerson PC, Blanchard C, et al.: Identification of a cooperative mechanism involving IL-13 and eotaxin-2 in experimental allergic lung inflammation. J Biol Chem 2005, 280:13952–13961. Teran LM, Mochizuki M, Bartels J, et al.: Th1-and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts. Am J Respir Cell Mol Biol 1999, 20:777–786. Pepe C, Foley S, Shannon J, et al.: Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol 2005, 116:544–549. Fryer AD, Stein LH, Nie Z, et al.: Neuronal eotaxin and the effects of ccr3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J Clin Invest 2006, 116:228–236.